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Abstract
Background: The interaction between Mycobacterium tuberculosis (Mtb) and host cells is complex and far from being
understood. The role of the different receptor(s) implicated in the recognition of Mtb in particular remains poorly defined,
and those that have been found to have activity in vitro were subsequently shown to be redundant in vivo.
Methods and Findings: To identify novel receptors involved in the recognition of Mtb, we screened a macrophage cDNA
library and identified scavenger receptor B class 1 (SR-B1) as a receptor for mycobacteria. SR-B1 has been well-described as a
lipoprotein receptor which mediates both the selective uptake of cholesteryl esters and the efflux of cholesterol, and has
also recently been implicated in the recognition of other pathogens. We show here that mycobacteria can bind directly to
SR-B1 on transfected cells, and that this interaction could be inhibited in the presence of a specific antibody to SR-B1, serum
or LDL. We define a variety of macrophage populations, including alveolar macrophages, that express this receptor,
however, no differences in the recognition and response to mycobacteria were observed in macrophages isolated from SR-
B12/2 or wild type mice in vitro. Moreover, when wild type and SR-B12/2 animals were infected with a low dose of Mtb (100
CFU/mouse) there were no alterations in survival, bacterial burdens, granuloma formation or cytokine production in the
lung. However, significant reduction in the production of TNF, IFNc, and IL10 were observed in SR-B12/2 mice following
infection with a high dose of Mtb (1000 CFU/mouse), which marginally affected the size of inflammatory foci but did not
influence bacterial burdens. Deficiency of SR-B1 also had no effect on resistance to disease under conditions of varying
dietary cholesterol. We did observe, however, that the presence of high levels of cholesterol in the diet significantly
enhanced the bacterial burdens in the lung, but this was independent of SR-B1.
Conclusion: SR-B1 is involved in mycobacterial recognition, but this receptor plays only a minor role in anti-mycobacterial
immunity in vivo. Like many other receptors for these pathogens, the loss of SR-B1 can be functionally compensated for
under normal conditions.
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Introduction
Tuberculosis is the leading cause of death worldwide from a
single infectious disease. The causative agent, Mycobacterium
tuberculosis (Mtb), enters the host typically via aerosols, and alveolar
macrophages are considered the first cells to engulf Mtb and
become infected. Although the initial interaction of the pathogen
with the host macrophage is considered a critical step in the
pathogenesis of Mtb, the role of the receptors that play a role in
mediating the entry of Mtb into macrophages and in transducing
intracellular signals is very controversial and far from being
understood. Over the years, more than a dozen receptors have
been shown to recognize and bind mycobacteria (reviewed in [1]).
However, the role of these receptors has been mostly based on in
vitro examination in transfected cells; studies using inhibitors or
animals deficient for specific receptors have indicated that these
receptors are dispensable [2–7]. Since no direct functional-based
search for the macrophage receptors involved in mycobacterial
recognition has been performed, here we utilised a generalized
screening method [8] with which we identified scavenger receptor
B class 1 (SR-B1) as a novel macrophage receptor involved in the
recognition of Mtb.
Scavenger receptors belong to a family of cell surface
transmembrane glycoproteins with broad ligand-binding abilities
and important roles in atherogenesis, innate immunity and
macrophage regulation (reviewed in [9]). Although their impact
for recognition of Mtb has not been extensively studied, there are a
few reports that show the general involvement of scavenger
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receptors in binding of mycobacteria [2,10]. Recently, the
scavenger receptors MARCO and SR-A were shown to be
involved in binding of cord factor [11].
Scavenger receptor B1, in particular, has been well-described as
a lipoprotein receptor which is expressed primarily in liver and
nonplacental steroidogenic tissues, and mediates both the selective
uptake of cholesteryl esters and the efflux of cholesterol [12–14]. A
member of the CD36 family of scavenger receptors, SR-B1
consists of 509 amino acids and is expressed as a 82kDa
glycoprotein with two cytoplasmic C- and N-terminal domains
separated by a large extracellular domain [15]. This receptor has
been shown to interact with both native and chemically modified
(oxidized and acetylated) low-density lipoprotein (LDL), high-
density lipoprotein (HDL), very-low-density lipoprotein and
anionic phospholipids [12,16–18]. Accumulating evidence sug-
gests that the function of SR-B1 as well as other members of the
CD36 family is not solely linked to cholesterol metabolism but
involves a wide spectrum of activities, including microbial
recognition. For example, the human homologue CLA-1 as well
as the Drosophila homologue Pes have been shown to mediate
binding and uptake of various bacteria, including both Gram+ and
Gram2 organisms [19,20] with Pes being the only member of the
CD36 family so far that has been described to be involved in
mycobacterial recognition [19]. Furthermore, SR-B1 was shown
to mediate the entry of hepatitis C virus (HCV) in an HDL-
dependent manner [21,22], while it also plays an important role in
the infection of hepatocytes by the malaria parasite [23].
Here we have identified SR-B1 as a receptor for mycobacteria,
and show that it can mediate the binding of mycobacteria in vitro.
However, we found that SRBI plays only a minor role in vivo and
that its function can be compensated for by other macrophage
receptors.
Results
Identification of SR-B1 as a Macrophage Receptor
Involved in Binding of Mycobacteria
To identify new receptors involved in binding and recognition
of mycobacteria, a retroviral cDNA expression library, generated
from RAW264.7 macrophages [24], was stably expressed in
NIH3T3 cells and visually screened by fluorescent microscopy for
binding of live Mycobacterium bovis bacillus Calmette-Gue´rin
expressing Green Fluorescent Protein (BCG-GFP). Positive cells
were isolated and enriched in culture until almost pure colonies of
BCG-binding cells were obtained. After isolation of their genomic
DNA and re-amplification of the stably inserted cDNA fragments
originating from the RAW264.7 library, a 2.5kb cDNA fragment
corresponding to the full-length murine scavenger receptor B class
1 (SR-B1) was obtained that was tested positive for BCG-GFP
binding when re-inserted into NIH3T3 cells (Fig. 1A). When
quantified for mycobacterial binding using luciferase expressing
BCG cells (BCG-lux) the SR-B1 expressing NIH3T3 revealed a 7-
fold increase in BCG binding compared to vector control cells
(Fig. 1B). To include a positive control for BCG-binding, NIH3T3
cells stably expressing SIGNR1 [25] were used, and these cells
showed slightly more mycobacterial binding of about 12-fold
versus controls (Fig. 1A and B).
Characterization of Mycobacterial Binding to SR-B1 In
Vitro Using Transfected Cells
To test BCG binding in cells which do not express any
endogenous SR-B1, we screened several cell lines by Western
blotting. Using this approach, we found that R6F cells were
negative for SR-B1, while both NIH3T3 cells and RAW264.7
macrophages expressed this receptor (Fig. 1C). We therefore
generated R6F cells stably expressing SR-B1 or SIGNR1 (as a
positive control) and tested their receptor expression by FACS
(Fig. 1D). These cells were also functionally tested for binding of
known ligands for the respective receptors, including DiI-labeled
LDL (Fig. 1E, [16]), for SR-B1, and zymosan (Fig. 1F, [25]), for
SIGNRI.
SR-B1 is a lipoprotein receptor, and we observed a significant
decrease in the binding of BCG-lux to R6F cells expressing SR-B1
when binding was performed in the presence of serum (Fig. 2A,
left panel). Notably, binding of mycobacteria to SR-B1 transfected
cells, although reduced, still occurred in the presence of serum. To
further investigate whether the serum-inhibition of bacterial
binding was direct or indirect, we performed experiments where
BCG-lux was pre-incubated in medium in the presence or absence
of serum and then added to SR-B1 expressing cells in the presence
or absence of serum (Fig. 2B, left panel). The bacteria pre-
incubated in the absence of serum were inhibited by serum, as
observed before (see Fig. 2A, left panel). A similar effect was
observed when the bacteria were pre-incubated in the presence of
serum; binding of these bacteria was only inhibited by the presence
of serum during the binding assay. Importantly, pre-incubation of
the bacteria in serum did not affect subsequent binding to the SR-
B1 expressing cells in the absence of serum. Therefore the serum-
inhibition effect was due to direct competition of serum
components for the receptor rather than an ‘‘opsonization’’ effect
on the bacteria. Based on this finding, all later experiments were
performed in the absence of serum.
To further demonstrate this competition, we performed binding
experiments in the presence of LDL in serum-free medium.
Although SR-B1 is known to have broad ligand specificity [15],
and recognizes various different lipoprotein classes, we chose
unmodified LDL as this particle has shown to bind specifically to
SR-B1 but not CD36 or class A scavenger receptors [16]. As
shown in Fig. 2C (left panel), both LDL and serum significantly
blocked binding of BCG-lux to SR-B1 expressing R6F cells, while
this effect was not observed in R6F cells expressing SIGNR1. We
also observed that bronchoalveolar lavage containing lung
surfactant significantly blocked binding of BCG-lux to SR-B1
transfected cells (Fig. 2D).
As mentioned above, SR-B1 is well characterised regarding its
role in cholesterol metabolism. Also, it is known that mycobacteria
can bind to free cholesterol in the membrane [26]. Therefore
experiments were designed to investigate whether the observed
binding of BCG-lux to cells expressing SR-B1 was due to direct
interaction of the bacteria with the receptor, or because of an
increased accumulation of cholesterol in the membrane. To this
end, the binding of BCG-lux to SR-B1 was investigated after
blocking of the receptor with a specific antibody. As shown in
Fig. 2E (left panel) SR-B1 expressing R6F cells pre-incubated with
anti-SR-B1 showed a significant reduction in binding of BCG-lux,
whereas the antibody had no affect on the binding of the
mycobacteria to control SIGNR1 cells. This was further supported
by the observation that depletion of the membrane’s cholesterol by
cyclodextrins did not significantly reduce the amount of BCG-lux
binding to R6F cells expressing SR-B1 (Fig. 2F), although SR-B1
transfected R6F cells did show more cholesterol accumulation
when stained with filipin compared to control cells (data not
shown).
We next wanted to test whether these results also held true for
virulent Mycobacterium tuberculosis H37Rv. Although we had some
difficulty in generating uniform suspensions of this bacterium
which interfered with our binding assays, all the trends observed
with BCG-lux could be confirmed with Mtb (Fig. 2A–E; right
M. tuberculosis and SR-B1
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Figure 1. Identification of SR-B1 as a receptor for mycobacteria. NIH3T3 cells stably transfected with empty vector pFBneo (negative control),
SR-B1 or SIGNR1 (positive control), respectively, were incubated with BCG-GFP (A) or BCG-lux (B) and assessed for binding by fluorescence microscopy
or luciferase activity, respectively. Shown is the x-fold increase of luciferase activity compared to vector control which was set as 1. Experiments were
performed in triplicate and normalised to cell number by CFSE staining. (C) Western Blot showing expression of SR-B1 in various untransfected cell
lines as indicated. Cellular lysates from rat liver were included as a control, and GAPDH served as loading control. (D) FACS analysis of R6F cells stably
transduced with pFB (vector control), SR-B1 or SIGNR1, and stained with anti-SR-B1 or anti-SIGNRI, as indicated. (E) FACS assay showing binding/
uptake of DiI-LDL to R6F cells stably expressing pFB (vector control), SR-B1 or SIGNR1. (F) Binding of FITC-labelled zymosan to R6F cells stably
expressing pFB (vector control), SR-B1 or SIGNR1, as quantified by fluorometry. Shown is the x-fold increase of fluorescence compared to vector
control which was set as 1. Experiments were performed in triplicate and normalised to cell number by CFSE staining.
doi:10.1371/journal.pone.0008448.g001
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Figure 2. Characterization of BCG and Mtb binding to SR-B1 transfected cells. R6F cells stably transfected with the indicated constructs
were incubated with either BCG-lux (left panels) or Mtb-lux (right panels), and quantified for binding by measuring luciferase activity. Experiments
were performed in triplicate and normalised to cell number by CFSE staining. (A) Quantification of mycobacterial binding to SR-B1 expressing cells
(white bars) or vector control cells (black bars) in the presence or absence of serum, as indicated. Shown is the x-fold increase of luciferase activity
compared to vector control which was set as 1. (B) Mycobacteria (BCG-lux or Mtb-lux) were pre-incubated in medium with or without 10% serum,
prior binding to R6F-SR-B1 cells also in the presence or absence of 10% serum. Shown is % of luciferase activity relative to binding to R6F-SR-B1 cells
in the absence of serum, which was set at 100%. (C) Effect of LDL on binding of mycobacteria to R6F cells expressing SR-B1 or SIGNR1, as indicated.
Shown is % of luciferase activity relative to R6F-SR-B1 or R6F-SIGNR1 cells, respectively, in the absence of additives. (D) Effect of BAL fluid and serum
(as a control) on binding of BCG-lux or Mtb-lux to SR-B1 expressing R6F cells. Shown is % of luciferase activity relative to R6F-SR-B1 in the absence of
additives. (E) Effect of anti-SR-B1 antibodies on binding of BCG-lux or Mtb-lux to SR-B1 or SIGNR1 transfected R6F cells. The white bars show % of
luciferase activity relative to binding in the absence of antibody (black bars). (F) SR-B1 expressing R6F cells were incubated with mycobacteria in the
presence of increasing concentrations of MbCD. Binding of BCG-lux is shown as % of luciferase activity relative to control (no MbCD).
doi:10.1371/journal.pone.0008448.g002
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panels). Importantly, Mtb-lux bound to SR-B1 transfected R6F
cells and this binding could be inhibited by the presence of serum,
LDL and BAL (Fig. 2A, C and D, right panels), which was due to
direct competition for the receptor (Fig. 2B, right panel). Further,
the binding of Mtb-lux to SR-B1 expressing cells could be
inhibited in the presence of an antibody against SR-B1 (Fig. 2E,
right panel). Thus overall, these data suggest that SR-B1 can
directly recognize mycobacteria and that this interaction can be
inhibited by serum and surfactant components.
The Role of SR-B1 for Mycobacterial Infection of Primary
Cells
Having demonstrated that SR-B1 can mediate the recognition
of mycobacteria in transfected cells, we next investigated the
contribution of this receptor on primary cells. Initially, different
macrophage populations (alveolar macrophages, bone-marrow
derived macrophages (BMDmØ), resident as well as thioglycollate-
elicited peritoneal macrophages) were isolated from wild type
C57BL/6 mice and tested for the expression of SR-B1 by Western
Blotting (Fig. 3A). This analysis demonstrated the expression of
this receptor on all macrophage populations examined, and was
absent in macrophages derived from SR-B12/2 mice. Important-
ly, alveolar macrophages and BMDmØ expressed highly SR-B1,
therefore these cell populations were tested for binding of BCG-lux
(Fig. 3B). Surprisinlgy, no statistically significant differences in
binding could be observed between wild type and SR-B12/2
macrophages in the absence of serum. Notably, mycobacterial
binding to resident alveolar macrophages was inefficient when
compared to BMDmØ, as has been demonstrated in a previous
study [27].
When analysed for TNF production 4 hr or 24 hr after
mycobacterial binding, no differences between wild type and
SR-B12/2 macrophages were detected (Fig. 3C). Although the
level of TNF was equally low after 4 hr in both macrophage
populations, it increased considerably in BMDmØ after 24 hr,
presumably reflecting the differences in bacterial binding as
described above. These experiments were repeated with varying
parameters in bacterial binding, including different incubation
times and temperatures, but no differences between wild type and
SR-B12/2 macrophages were detected under any of the
conditions tested (data not shown). We also found that the
presence of serum inhibited binding of mycobacteria to BMDmØ
equally well in both wild type and SR-B12/2 macrophages, while
the addition of MbCD (to deplete cholesterol membrane) had no
effect on binding (data not shown). Furthermore, when we blocked
SR-B1 with a specific antibody, binding of mycobacteria to the
macrophages was unaltered compared to untreated controls (data
not shown). Finally we investigated whether the survival of
mycobacteria in macrophages was affected by the presence or
absence of SR-B1. To this end, wild type and SR-B12/2
BMDmØ were infected with BCG-lux and mycobacterial viability
analysed over time by measuring luciferase activity. As shown in
Fig. 3D, both wild type and SR2B12/2 macrophages could
equally efficiently kill mycobacteria within the first 24 hr after
infection, following which the bacteria started to replicate. Thus
loss of SR-B1 has minimal impact on mycobacterial recognition by
primary macrophages in vitro.
SR-B1 Is Dispensable for Infection with Mycobacterium
tuberculosis In Vivo
To explore a potential role for SR-B1 in vivo, wild type and SR-
B12/2 mice were aerosol infected with 100 CFU Mycobacterium
tuberculosis H37Rv, and the development of disease monitored after
2 and 4 months. As shown in Fig. 4A, both wild type and SR-
B12/2 mice survived and gained weight throughout the course of
the infection. The lungs of both groups displayed inflammatory
foci, consisting of patchy infiltrates of inflammatory cells,
predominantly foamy macrophages (Fig. 4B). Typical granulomas
were not observed. Some SR-B12/2 mice showed evidence of
clefts of accumulated cholesterol, which were not observed in the
wild type animals (Fig. 4B and data not shown). When the sizes of
inflammatory foci were measured by morphometric analysis
(Fig. 4C), SR-B12/2 mice did not show significant differences to
the wild type mice. Furthermore, no differences in bacterial
burdens (Fig. 4D) or production of TNF, IFNc, IL10, IL12p70 or
IL6 (Fig. 4E) were detected between wild type and SR-B12/2
mice.
We also tested the effects of infection with a high dose of Mtb,
i.e 1000 CFU per lung (Fig. 5). As before, both groups of mice
gained weight and did not display any adverse effects during the
course of the infection (Fig. 5A). Although we detected significantly
less pulmonary TNF, IL10 and IFNc in the SR-B12/2 animals
(Fig. 5C), this did not correlate with differences in bacterial
burdens (Fig. 5B). Although the inflammatory pathology was
similar between both groups of mice, except for the presence of
occasional cholesterol clefts (Fig. 5D and data not shown), the size
of the inflammatory foci in the SR-B12/2 mice were found to be
slightly increased (p-value of 0.032) (Fig. 5E).
Elevated serum cholesterol levels are known to correlate with
susceptibility to tuberculosis [28], and as SR-B1 is involved in
cholesterol metabolism, we assessed the influence of cholesterol in
the diet on susceptibility to mycobacterial infection in wild type
and SR-B12/2 mice. Appropriate numbers of animals were fed
either a low cholesterol (LC, 0.15% cholesterol) or a high
cholesterol (HC, 1.25% cholesterol) diet and then infected with
100 CFU Mtb. Cholesterol levels at the time of infection were
significantly higher in SR-B12/2mice compared to wild type mice
on either diet, and higher levels of cholesterol were detected in SR-
B12/2 mice on the HC diet compared to animals on the LC diet
(Fig. 6A). As observed in our previous experiments (Fig. 4A and
5A), all animals gained weight and did not show any adverse
effects during the course of the infection (Fig. 6B). When the
experiment was terminated after 4 months, there were similar
relative differences between the various mouse strains in serum
cholesterol levels, although the SR-B12/2 mice showed an overall
general increase (Fig. 6C, compare with Fig. 6A). We also
observed a slight, but significant, diet-dependent difference in
bacterial burden of the lungs, with elevated bacterial levels in both
wild type and SR-B12/2 mice on the HC diet compared to the
corresponding animals on the LC diet (Fig. 6E). However, there
was no difference in bacterial burden between wild type and SR-
B12/2 mice on either diet (Fig. 6E). Despite the slightly elevated
bacterial burdens in mice on HC diets, there were no significant
differences in histopathology, except for the occasional presence of
cholesterol clefts in SR-B12/2 lungs (Fig. 6D), or in the levels of
pulmonary cytokine (Fig. 6F).
Discussion
The identification of host pattern recognition receptors that
recognise Mtb represents a potential opportunity for anti-
mycobacterial prophylaxis, as the interruption of binding may
functionally disrupt Mtb entry into its host cell niche. By screening
a retroviral cDNA expression library derived from RAW264.7
murine macrophages, we identified SR-B1 as a receptor for
mycobacteria (Fig. 1A and B). As a member of the CD36 family of
scavenger receptors, which have been well described for their
M. tuberculosis and SR-B1
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function in cholesterol metabolism, we show here that SR-B1 is
also involved in mycobacterial recognition. To our knowledge, this
activity so far has only been attributed to the Drosophila homologue
Pes [19].
As SR-B1 is involved in cholesterol transport across the
membrane [12–14] and as mycobacteria have been shown to
display high binding capacity for free cholesterol [26], we
wondered if the expression of SR-B1 would lead to an
accumulation of cholesterol in the membrane and indirectly lead
to increased mycobacterial binding. However, depletion of the
membrane’s cholesterol by cyclodextrins did not significantly
reduce mycobacterial binding to SR-B1 expressing cells (Fig. 2F).
This is supported by an earlier study on SR-B1 expression of
transfected COS-7 cells, where the presence of SR-B1 had no
effect on the level of free cholesterol [29]. We also demonstrated
that mycobacteria bound directly to SR-B1, and that this binding
could be competitively inhibited by specific antibodies, lipids,
serum and surfactant (Fig. 2A–E).
While we clearly show that SR-B1 is involved in recognition of
mycobacteria on transfected cells we could not define a role for
Figure 3. The role of SR-B1 in mycobacterial recognition in primary cells. (A) Western Blot assessing expression of SR-B1 in different
macrophage populations derived from wild type C57/BL6 and SR-B12/2 mice, as indicated. (B) Alveolar macrophages and BMDmØ isolated from wild
type (black bars) and SR-B12/2 mice (white bars) were tested for BCG-lux binding in the absence of serum. Shown is the relative luciferase activity
(R.L.U.), normalised to cell number by CFSE staining. (C) TNF production at 4 hr or 24 hr after binding of BCG-lux to alveolar macrophages or BMDmØ
isolated from wild type (black bars) and SR-B12/2 mice (white bars). Shown is x-fold increase in TNF production relative to control (no BCG binding).
Experiments were normalised to cell number by CFSE staining. (D) Survival of BCG-lux in infected BMDmØ isolated from wild type (solid lines) and SR-
B12/2 mice (dashed lines). After infection of macrophages, unbound mycobacteria were removed and samples taken after the indicated time points
to assess luciferase activity. Experiments were performed in triplicate, normalised to cell number by CFSE staining and shown as R.L.U. relative to time
point 1.
doi:10.1371/journal.pone.0008448.g003
M. tuberculosis and SR-B1
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Figure 4. The role of SR-B1 in vivo following low dose infection with Mtb.Wild type C57/BL6 and SR-B12/2mice were infected with 100 CFU
Mycobacterium tuberculosis H37Rv by aerosol route and sacrificed after 2 and 4 months. (A) Body weight was monitored throughout the course of the
experiment and is presented as % of original body weight (time of infection) with the SEM shown as solid lines for wild type animals and dashed lines
for SR-B12/2 mice. Lungs of infected animals were analysed at 2 and 4 months for histopathology by H&E staining (B). Also shown is a lung section
showing the presence of clefts of accumulated cholesterol that were observed in some inflammatory foci in infected SR-B12/2 mice. Lung sections
after 4 months of infection were further anlaysed by morphometric analysis to calculate the sizes of the inflammatory lesions (C). Lung homogenates
were analysed at 2 and 4 months for bacterial burden (D), as well as the production of TNF, IFNc, IL10, IL12p70 and IL6 (E) with the black circles
representing wild type and the open circles representing SR-B12/2 animals. Shown are the data from individual mice and the median value.
doi:10.1371/journal.pone.0008448.g004
M. tuberculosis and SR-B1
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Figure 5. The role of SR-B1 in vivo following high dose infection with Mtb. Wild type C57/BL6 and SR-B12/2 mice were infected with 1000
CFU Mycobacterium tuberculosis H37Rv by aerosol route and sacrificed after 4 months. (A) Body weight was monitored throughout the course of the
experiment and is presented as % of original body weight (time of infection) with the SEM shown as solid lines for wild type animals and dashed lines
for SR-B12/2 mice. Lungs of infected animals were analysed for bacterial burden (B), TNF, IFNc, IL10, IL12p70 and IL6 (C), histopathology (D) and
inflammatory lesion size (E), with the black circles representing wild type and the open circles representing SR-B12/2 animals. Shown are the data
from individual mice and the median value. *, p,0.05.
doi:10.1371/journal.pone.0008448.g005
M. tuberculosis and SR-B1
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Figure 6. The effect of cholesterol in SR-B12/2 mice during Mtb infection. Wild type C57/BL6 and SR-B12/2 mice were fed either a low
cholesterol diet (LC, 0.15% cholesterol) or a high cholesterol diet (HC, 1.25% cholesterol) throughout the experiment, infected with 100 CFU
Mycobacterium tuberculosis H37Rv by aerosol route and sacrificed after 4 months. (A) Levels of serum cholesterol following 2 weeks on the various
diets, as indicated, prior to infection (black bars representing wild type, and white bars the SR-B12/2 animals). (B) Average mouse weight throughout
the course of the experiment, presented as % of original body weight 6SEM. 4 months after infection the mice were analyzed for serum cholesterol
(C), histopathology (D), bacterial burdens (E), and pulmonary TNF, IFNc, IL10, IL12p70 and IL6 (F) with the black circles representing wild type and the
open circles representing SR-B12/2 animals. Shown are the data from individual mice and the median value. *, p,0.05.
doi:10.1371/journal.pone.0008448.g006
M. tuberculosis and SR-B1
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this receptor in primary cells, although SR-B1 was clearly
expressed in wild type macrophages (Fig. 3A) as has been shown
earlier for the macrophage cell line RAW264.7 [30]. While
disappointing, this was not entirely unexpected, as another study
investigating the human homologue of SR-B1, was shown to
recognise Gram positive and Gram negative bacteria in transfect-
ed, but not in primary cells [20].
Studies on primary macrophages revealed no difference in
binding of mycobacteria and subsequent TNF production in the
presence or absence of SR-B1 (Fig. 3B and C). However, binding
of mycobacteria to both wild type and SR-B12/2 BMDmØ was
much stronger than to alveolar macrophages (Fig. 3B), and this is
likely to be due to the expression of other recognition receptors on
these cells, as has been shown previously [11,31]. We also found
that serum blocked binding of mycobacteria to both wild type and
SR-B12/2 alveolar macrophages and BMDmØ (data not shown)
as opposed to an earlier observation where serum components
increased binding to BMDmØ [31]. Furthermore, depletion of the
membrane’s cholesterol with MbCD had no effect on binding
(data not shown), which is in contrast to a previous study [26].
This can be due to different macrophage populations, preparation
techniques and different sera used. Also, other macrophage
receptors might be more important for mycobacterial binding
which render the role of the cholesterol content in the membrane
redundant.
Our in vivo studies on the role of SR-B1 during mycobacterial
infection also revealed no substantial difference between wild type
and SR-B12/2 mice when infected with either a low or a high
dose Mtb or when investigated in the context of dietary cholesterol
(Fig. 4D, Fig. 5B, Fig. 6E). However, we did observe some clefts of
accumulated cholesterol, limited largely to the peripheral paren-
chyma, in the absence of SR-B1 after Mtb infection (Fig. 4B). The
accumulation of cholesterol in the inflammatory lesions of the SR-
B12/2 mouse lungs might account for the fact that cholesterol
transport across the macrophage membrane is impaired in these
animals. Although we did detect decreased levels of TNF, IFNc
and IL10 in the SR-B12/2 animals infected with a high dose Mtb
(Fig. 5C), the bacterial burdens in both groups of animals was
comparable (Fig. 5B). In fact, there were still substantial amounts
of TNF and IFNc present in the SR-B12/2 lungs: 76% TNF and
63% IFNc levels compared to those found in wild type animals,
while the amount of IL10 was decreased to 40% compared to wild
type. While the changes in cytokine levels are likely to have
contributed to the slight difference in size of the inflammatory
lesions that were observed following infection with a high dose
Mtb (Fig. 5E), we do not feel these data represent a significant
biological difference between wild type and knockout animals.
The lack of a substantial effect of SR-B1 deficiency was
surprising, however, considering the elevated serum cholesterol
levels in SR-B12/2 mice (Fig. 6A and C). Indeed, a recent report
demonstrated that high serum cholesterol levels in apolipoprotein
E (ApoE) deficient mice fed on a HC diet, resulted in high
susceptibility of to Mtb [28], although ApoE appeared to have a
more pronounced influence on the regulation of plasma
cholesterol than SR-B1. However, there were significantly
increased bacterial numbers in the lungs of infected wild type
and SR-B12/2 animals fed on the HC diet compared to mice on
the LC diet (Fig. 6E), which was independent of SR-B1, and,
interestingly, did not appear to correlate with the serum
cholesterol levels (Fig. 6C and 6E). Although not detectable in
the serum, animals fed the HC diet might still have elevated
intracellular cholesterol stores which can be taken up and used by
Mtb as a source of energy to their growth advantage [32]. This
might explain why those animals on the HC diet displayed higher
bacterial burdens in the lungs compared to those fed a LC diet.
However, the role of SR-B1 for mycobacterial growth seems to be
minor and independent of the diet.
While playing a role for recognition of mycobacteria in an
isolated context using transfected cells, our data supports the
notion that macrophage receptors show redundancy when
investigated in primary cells [1,33]. This is true, for example,
with the mannose receptor (MR), which has long been considered
to play a central role in mycobacterial phagocytosis [34], and for
the TLRs, which have recently emerged to contribute to the innate
recognition of these pathogens [35,36]. The situation is even more
complex in vivo. Receptors such as CR3, for example, which is able
to mediate both complement-opsonized as well as non-opsonized
phagocytosis of mycobacteria in vitro on transfected cells [37] was
not found to play a role in vivo [4]. Similarly contradicting findings
have been described for the TLRs: although important in vitro [38],
TLR2, TLR4, or mice triply deficient in TLR2, TLR4 and TLR9
[5,6,39] were infected with mycobacteria, no susceptibility to Mtb
was observed. However, these data were contradicted by other
groups showing that TLR2 and TLR4 do play roles in controlling
the infection with Mtb [40,41]. This clearly shows that when
studying the interaction of Mtb with its host in vivo the particular
experimental setting greatly affects the outcome.
In this context, the preparation of the mycobacteria has much
influence on the experimental observations: we and others found
that mycobacteria bind to and activate macrophages to a much
greater extent when sonicated rather than syringed ([42] and data
not shown). Also, when performing the binding assay under shear
conditions rather than static binding one would simulate the
dynamic and physiological conditions in the lung much better and
select for higher-affinity receptors [43]. With the static binding
conditions as presented here, one would also identify low-affinity
receptors. It is possible that SR-B1, being a true scavenger with
broad ligand specificity, is a low-affinity receptor for mycobacteria
and simply plays only a minor role in vivo. Experimental differences
will also occur when different strains of mycobacteria (virulent vs.
avirulent) and/or genetic background of the receptor-deficient
mice (relatively resistant such as C57BL/6 vs. relatively susceptible
such as BALB/c) are being used. To add to the complexity,
different macrophage populations (i.e. resident vs. elicited vs.
immune-activated as well as human vs. murine) express a different
array of receptors [11,27] and therefore respond differently to
infection with Mtb. This is also important in our experimental
approach: we identified SR-B1 when screening a cDNA library
generated from the murine macrophage cell line RAW264.7.
These cells might express a completely different array of receptors
compared to primary cells, leading to the identification of Mtb-
binding surface molecules that might not be relevant in vivo.
As discussed in the literature before, it seems that Mtb enters the
host cell via a number of possible receptor/ligand interactions
[1,33]. The ability of Mtb to engage multiple receptors (or
receptor clusters) simultaneously might be an evolutionary
advantage for its pathogenesis: in the absence of a single receptor,
phagocyte infection by mycobacteria can be efficiently supported
by alternative receptors.
Taken together, we demonstrate that SR-B1 is another example
of the diverse spectrum of receptors that recognize mycobacteria in
vitro but is redundant in the extremely complex macrophage-
mycobacterium interaction in vivo. On the one hand, this
redundancy of SR-B1 in mycobacterial infection might be a
result, at least in part, of surfactant blocking the bacterial-receptor
interactions, as we demonstrated in vitro (Fig. 2D). Surfactant may
directly compete with Mtb for the receptor binding site, or that
aggregated mycobacteria alter their interaction with the host cells,
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as shown for SP-D [44,45]. On the other hand, the redundancy
may stem from down-regulation of this receptor during mycobac-
terial infection, as macrophage activation has been shown to
suppress SR-B1 expression [30]. Furthermore, expression of the
related human scavenger receptor CD36 has been found to be
lower on monocytes in TB patients, and reverse to normal levels
upon anti-mycobacterial treatment [46]. At the same time, when
resident alveolar macrophages differentiate by cytokine stimula-
tion, they increase the expression of surface receptors and show a
higher affinity to bind mycobacteria [27], therefore maybe
completely render any role of SR-B1 redundant.
Materials and Methods
Cell Culture
NIH3T3 murine embryonic fibroblasts (ATCC), RAW264.7
murine macrophages (ATCC), rat 6 fibroblasts (R6F, [47]) and the
packaging cell line plat-E [48] were grown in DMEM (Invitrogen)
supplemented with 10% heat-inactivated fetal calf serum (Delta
Bioproducts), 2mM L-glutamine, 100U/ml penicillin and 100mg/
ml streptomycin (Sigma) in a humidified atmosphere (5% CO2) at
37uC, if not otherwise indicated.
Ligand Binding Assays
The cells used for the binding assays were plated in 24-well-
plates at a density of 56104 cells per well and allowed to adhere
overnight. Nonopsonic binding studies were performed with live
strains of Mycobacterium bovis bacilli Calmette-Gue´rin (BCG)
expressing either Green Fluorescent Protein (BCG-GFP) or
bacterial luciferase (BCG-lux) as well as Mycobacterium tuberculosis
H37Rv expressing bacterial luciferase [49] (Mtb-lux) and FITC-
labeled zymosan (Molecular Probes). Mycobacteria were grown in
Middlebrook 7H9 (Difco) with 10% OADC (oleic acid, albumin,
dextrose, catalase) enrichment in the presence of 10mg/ml
kanamycin (BCG-GFP) or 50mg/ml hygromycin (BCG-lux),
respectively, and kept as 15% glycerol stocks at 280uC at a
density of approximately 56106 particles. For binding studies,
BCG or Mtb aliquots were thawed, spun in a microcentrifuge for
1 min at 13000g, washed twice in DMEM followed by vigorous
vortexing, and aggregates were dispersed by sonication for 30 sec
at 50W in a cuphorn sonicator. To infect cells, culture medium
was removed, and mycobacterial suspension in serum-free DMEM
(if not otherwise indicated) was added at a particle:cell ratio of
10:1. Where indicated, binding was performed in the presence of
additives such as 10% serum, 1:100 diluted rabbit anti-mouse SR-
B1 polyclonal antibody (NB 400-134, Novus Biologicals), 100mg/
ml LDL, 50% bronchoalveolar lavage fluid (BAL), or methyl-b-
cyclodextrin (MbCD, Sigma), respectively, at the indicated
concentrations. FITC-labeled zymosan was prepared similarly,
sonicated for 3 min at 150W and added to the indicated cells at a
particle:cell ratio of 10:1. The cells were then incubated with their
ligands for 1 hr at 37uC, washed three times with DMEM and
prepared for further analysis.
Quantification of BCG- and Zymosan Binding
Binding of BCG-lux to the cells was determined by lysis of the
cells in 150ml 0.1% triton X-100 and addition of 20ml 1% n-decyl-
aldehyde to initiate the luciferase reaction. Light emission was
measured in white 96-well plates for 2.5 sec using a Fluoroscan
Ascent FL (Thermo Fisher Scientific, Waltham, MA). Binding of
FITC-zymosan was quantified by lysis of the cells in 100ml 3%
triton X-100. The relative fluorescence was then determined in
black 96-well plates using the Fluoroscan Ascent FL. Both BCG-
and zymosan binding data were normalized to cell numbers by
fluorescently staining an independent set of samples with 5mM
CFSE (Molecular Probes) in PBS for 5 min at room temperature.
After three washes cells were lysed in 100ml 3% triton X-100 and
fluorescence was determined as above.
All experiments were performed in triplicates, repeated at least
three times and calculated as means6S.E. Values were expressed
as relative light units (R.L.U.) or relative fluorescence units
(R.F.U.), respectively, or as x-fold increases compared to controls.
Statistical significances were calculated using the Student’s t test
(*, p,0.05).
Expression and Functional Screening of a Retroviral
cDNA Library
A retroviral cDNA expression library generated from RAW264.7
macrophages cloned into the retroviral vector pFB-Neo (Stratagene)
was used for stable transduction of NIH3T3 cells as described [24].
Briefly, 16106 plat-E cells were transfected per 1mg DNA using
FuGENE 6 transfection reagent (Roche Applied Science) according
to the manufacturer’s instruction and incubated for 24 hr at 37uC,
followed by another 24 hr incubation at 32uC. Retroviral superna-
tants were harvested and used to transduce 16105 NIH3T3 cells in
the presence of 5mg/ml polybrene (Sigma), which were then selected
with 0.4mg/ml G418 (InvivoGen). The screening for cells expressing
any mycobacterial-binding receptors was done by fluorescent
microscopy as described in detail in [8] on a Zeiss inverted
microscope Axiovert 40 CFL after incubation of the stably transfected
NIH3T3 cells with M.bovis BCG expressing GFP prepared as
described above. Positive cells were ring-isolated using cloning
cylinders, expanded in culture for 4–7 days and re-screened until the
majority of cells were found to be positive. Viral cDNA inserts were
recovered from the genomic DNA of positive cells by conventional
PCR using the primers 59Retro and 39pFB-Neo (Stratagene) and
re-cloned into pFB-Neo for functional testing and sequencing.
DNA Constructs and Generation of Stable Cell Lines
The 2.5kb cDNA of SRB1 was derived from the functional
screen and subcloned into the retroviral vector pFB-Neo.
Subcloning of SIGNR1 in pFB-Neo has been described before
[25]. Stable NIH3T3 or R6F cells expressing SRB1 or SIGNR1
were generated by retroviral transduction as described above and
grown in the presence of 0.4mg/ml G418 (InvivoGen).
Western Blotting
Cells were lysed in Nonidet P-40 buffer (1% Nonidet P-40,
150mM NaCl, 10mM EDTA, 10mM NaN3, 10mM Tris-HCl
(pH 8), 2mM Na3VO4, 10mM NaF, and complete EDTA-free
protease inhibitors (Roche Applied Sciences) and incubated on ice
for 30 min. Nuclei and cell debris were pelleted at 12000g for
20 min at 4uC, and supernatants were prepared for SDS-PAGE
and Western blotting according to conventional protocols. Rabbit
anti-mouse SR-B1 IgG (NB400-104, Novus Biologicals) and goat
anti-rabbit IgG horseradish peroxidase conjugate (Jackson Im-
muno Research Laboratories, Inc.) were used to detect SR-B1
using ECL chemiluminescence substrate (Amersham Biosciences).
As a loading control the blots were probed with a rabbit anti-mouse
GAPDH monoclonal antibody (Cell Signaling Technology, Inc.).
Flow Cytometry
Flow cytometry was performed according to standard protocols
at 4uC. Briefly, adherent cells were lifted in 4mg/ml lidocaine
hydrochloride (Sigma) in PBS supplemented with 10mM EDTA,
washed in FACS wash solution (0.5% BSA in PBS) and placed at a
density of 16105 cells in 96-well V-bottom plastic plates. Cells
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were blocked with 5% BSA in PBS or 5% heat-inactivated rabbit
serum, respectively, and examined for the surface expression of
SR-B1 or SIGNR1 using rabbit polyclonal anti-mouse SR-B1 IgG
(NB400-113, Novus Biologicals) or rat monoclonal anti-mouse
ERTR9 IgM (BMA Biomedicals) together with biotinylated mouse
anti-rat IgM (Serotec), respectively. Rabbit IgG (Chromopure) or
rat IgM (BD PharMingen), respectively, were used as isotype
controls. Cells were stained with R-Phycoerythrin-conjugated
donkey anti-rabbit IgG (Jackson Immuno Research Laboratories,
Inc.) or R-Phycoerythrin-conjugated streptavidin (BD PharMin-
gen), respectively, and fixed with 1% formaldehyde in PBS. The
analysis was performed using a FACSCalibur (Becton Dickinson)
together with the software CellQuest version 4. For the detection
of ligand binding to SR-B1, 10mg/ml DiI-labelled LDL (Molecular
Probes) was added to SR-B1 expressing R6F cells in serum-free
DMEM for 2 hr at 37uC. Cells were then washed three times and
lifted with 4mg/ml lidocaine hydrochloride (Sigma) in PBS
supplemented with 10mM EDTA. Cells were spun down,
resuspended in FACS wash solution containing 1% formaldehyde
and analysed for ligand binding by FACS.
Animals
C57BL/6 mice deficient in SR-B1 and its splice variant SR-B2
(Scarb1tm1Kri/Scarb1tm1Kri) were purchased from the Jackson Labo-
ratory which were originally derived by Rigotti et al. [50]. Animals
were maintained under specific pathogen-free conditions in the
University of Cape Town animal facility. All work was approved
by the Faculty of Health Sciences Animal Ethics Committee,
University of Cape Town. As homozygous Scarb1tm1Kri/Scarb1tm1Kri
female mice were not fertile, breeding had to be performed with
heterozygous Scarb1tm1Kri/Scarb1+ mice. However, the numbers of
mutant offspring was significantly less than the expected
Mendelian ratio of 1:2:1 as described earlier [50,51], which
significantly limited the number of animals available for
experiments. Where indicated, mice were fed either a low
cholesterol (LC, 0.15% cholesterol) or a high cholesterol (HC,
1.25% cholesterol) diet (Research Diets, Inc.) two weeks before
and throughout the experiment. For these experiments, serum
cholesterol levels were measured using the Cholesterol Enzymatic
CHOD-PAP kit (KAT Laboratory & Medical (Pty) Ltd.).
Isolation of Primary Macrophages
Resident or thioglycollate-elicited peritoneal macrophages as
well as bone-marrow derived macrophages (BMDmØ) were
isolated from 8–12 weeks old SR-B12/2 mice or wild type
C57BL/6 littermates by standard procedures. To isolate resident
alveolar macrophages, lungs were lavaged with 1ml cold PBS
(representing the bronchoalveolar lavage (BAL)), followed by
repeated washes with 1ml PBS/10mM EDTA. Cells were
maintained for 24 hr in RPMI (Invitrogen) with 10% heat-
inactivated fetal calf serum (delta bioproducts), 2mM L-glutamine,
100U/ml penicillin and 100mg/ml streptomycin (Sigma) at 37uC,
except for BMDmØ which were cultured in RPMI medium for 5–
7 days supplemented with 20% (v/v) L-cell conditioned medium
as a source of M-CSF. Binding experiments with these
macrophages were performed in the absence of serum (and
absence of M-CSF, in the case of BMDmØ) as described above.
To determine the levels of TNF released into the supernatant, cells
were washed after the binding assay in a parallel set of
experiments, fresh DMEM containing 10% serum was added,
and cells were incubated at 37uC. The amount of TNF was
measured after 4 hr and 24 hr using the OptEIA murine TNFa
ELISA kit (BD Biosciences) as described by the manufacturers,
and normalized to cell number by CFSE staining. Data represent
pooled values from at least 3 independent experiments.
M. tuberculosis Infections
Frozen stocks of Mycobacterium tuberculosis H37Rv were thawed,
briefly vortexed, and clumping disrupted by aspirating 30 times
through a 29-gauge needle. The concentration was adjusted in
sterile saline to deliver ,100 CFU per mouse (low dose infection)
or ,1000 CFU per mouse (high dose infection). Appropriate
numbers of 10–14 weeks old SR-B12/2 male and female mice or
wild type C57BL/6 littermates were then infected via the aerosol
route using an inhalation exposure system (Glas-Col, Terre Haute,
IN). In each experiment five mice were sacrificed 24 hr post-
infection to confirm the infection dose. Animals were monitored
throughout the experiments with regard to body weight and signs
of disease. After 2 or 4 months, mice were sacrificed and lungs
were removed and weighed. Defined tissue aliquots were
homogenized in saline/0.04% Tween-80, and 10-fold serial
dilutions were plated in duplicates onto Middlebrook 7H10 agar
plates containing 10% OADC (Difco). Plates were incubated at
37uC, and colonies were counted after 3 weeks. Data are expressed
as CFU per lung.
Lung homogenates were further analysed to measure the
amounts of TNF, IFNc, IL10, IL12p70 and IL6 by ELISA with
appropriate OptEIA kits (BD Biosciences) as described by the
manufacturers.
Lungs were also prepared for histology by fixing the big lobes in
4% phosphate-buffered formalin and then embedding in paraffin.
5 mm-thick sections were stained with haematoxylin and eosin
(H&E) for evaluation of pathologic changes. The sizes of
inflammatory lesions in four serial sections per Mtb infected
mouse lung were determined by automated morphometry using a
Nikon inverted microscope eclipse 90i and the software NIS-
Elements BR 3.1 (Nikon).
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